Zobrazeno 1 - 10
of 2 130
pro vyhledávání: '"Wade, Oliver"'
Publikováno v:
In Annals of Oncology June 2004 15(6):928-932
Publikováno v:
American Journal of Clinical Oncology. 28:340-344
Colorectal cancers frequently overexpress the epidermal growth factor receptor. Gefitinib (Iressa), an inhibitor of the epidermal growth factor receptor tyrosine kinase, is synergistic with oxaliplatin in preclinical colon cancer models. The authors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46df001e404ff968b926b818e33c4b00
https://doi.org/10.1097/01.coc.0000159558.19631.d5
https://doi.org/10.1097/01.coc.0000159558.19631.d5
Autor:
David A. Taber, Everett E. Vokes, Kurombi Wade-Oliver, Hedy L. Kindler, Sridhar Mani, Edem Agamah, Mark J. Ratain, Apurva A. Desai
Publikováno v:
Cancer Chemotherapy and Pharmacology. 56:421-426
Introduction: Despite the extensive clinical experience with irinotecan, significant concerns remain regarding its toxicity. In a phase I trial, we modulated irinotecan pharmacokinetics by inhibiting biliary excretion of SN-38, the active metabolite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92fcc3d793f27b62ebf20536871b64d0
https://doi.org/10.1007/s00280-005-1020-5
https://doi.org/10.1007/s00280-005-1020-5
Autor:
Anjali Avadhani, Sridhar Mani, Theodore Karrison, Everett E. Vokes, Kurombi Wade-Oliver, Hedy L. Kindler
Publikováno v:
Investigational New Drugs. 22:323-327
9-Aminocamptothecin (9-AC) is a water-insoluble camptothecin derivative that demonstrated broad activity in pre-clinical studies. In vitro, greater anti-tumor efficacy can be achieved with prolonged administration. A minor response was observed in ga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d963b30628cd739a3c8258c12359780
https://doi.org/10.1023/b:drug.0000026259.28395.c2
https://doi.org/10.1023/b:drug.0000026259.28395.c2
Autor:
James L. Abbruzzese, Peter K. Tothy, Kurombi Wade-Oliver, Hedy L. Kindler, Sridhar Mani, Everett E. Vokes, Richard A. McCormack, Robert A. Wolff
Publikováno v:
Investigational new drugs. 23(5)
Background: Pancreaticobiliary malignancies respond poorly to conventional chemotherapy, and novel agents are needed. Dolatstatin-10 is a potent antimitotic pentapeptide isolated from the marine mollusk Dolabella auricularia that inhibits microtubule
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66f785a9642adf94d4a27bd1d036463d
https://pubmed.ncbi.nlm.nih.gov/16133801
https://pubmed.ncbi.nlm.nih.gov/16133801
Autor:
Cathy, Eng, Ramesh K, Ramanathan, Ramesh K, Ramathan, Michael K, Wong, Scot C, Remick, Lanting, Dai, Kurombi T, Wade-Oliver, Sridhar, Mani, Hedy L, Kindler
Publikováno v:
American journal of clinical oncology. 27(6)
Gemcitabine is a commonly used chemotherapy for biliary tree carcinomas, achieving response rates of 10% to 60%. Preclinical studies indicate that fixed dose rate infusion optimizes accumulation of gemcitabine triphosphate and may enhance the clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e8c72f4e161fcef5077cbcfcb1a97cc
https://pubmed.ncbi.nlm.nih.gov/15577433
https://pubmed.ncbi.nlm.nih.gov/15577433
Autor:
Kristen Kasza, Cathy Eng, Everett E. Vokes, Kurombi Wade-Oliver, Sreenivasa Nattam, Hedy L. Kindler, Rafat Ansari
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 15(6)
Background The epothilone B analog, BMS-247550, is a non-taxane microtubulin-stabilizing agent with preclinical activity in taxane-resistant cell lines and phase I activity in colorectal cancer. We conducted a phase II study of single-agent BMS-24755
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::218ed8d3817489981bf4ba44623229db
https://pubmed.ncbi.nlm.nih.gov/15151950
https://pubmed.ncbi.nlm.nih.gov/15151950
Autor:
Hedy L. Kindler, K. Wade-Oliver, Walter M. Stadler, Sreenivasa Nattam, James A. Wallace, Gershon Y. Locker, Kristen Kasza, E. E. Vokes
Publikováno v:
Journal of Clinical Oncology. 25:4608-4608
4608 Background: The ras oncogene is mutated in about 90% of PC, leading to constitutive activation of the Ras-Raf-MAPK signal transduction pathway. Sorafenib an inhibitor of B-raf, VEGFR2, and PDGFR-B, has in vitro activity against PC cell lines dep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::592443068a9aac538ab3626dd563a56d
https://doi.org/10.1200/jco.2007.25.18_suppl.4608
https://doi.org/10.1200/jco.2007.25.18_suppl.4608